A 2-year-old Indiana boy and his mother contracted a rare
and life-threatening infection from his soldier father's smallpox
vaccination, according to a published report.
The boy and his mother were being treated in a specially ventilated
room at the University of Chicago's Comer Children's Hospital,
the Chicago Tribune reported Saturday.
The family's name and home town were not released at their
request.
The boy developed a virulent rash over 80 percent of his body
earlier this month after coming in contact with his father,
who had recently been vaccinated for smallpox before he was
to be deployed overseas by the Army, the paper said.
Physicians stressed that the boy was not suffering from smallpox,
but from the related vaccinia virus which is used to convey
immunity to the much deadlier disease. They said the infection
was a rare condition called eczema vaccinatum, which has not
been reported since at least 1990, when the military ended a
previous program of smallpox vaccination. Smallpox was declared
eradicated in 1980.
The military began smallpox vaccinations again in 2002 because
of bioterrorism fears.
Doctors said the child suffered from eczema, which is a known
risk factor for vaccinia infection. People with eczema are warned
not to have close physical contact with the recently vaccinated
because the condition allows the virus to enter the skin, they
said.
The U.S. Defense Department and federal, state and local health
authorities have been in daily contact with the hospital about
the case. Health officials say there is no infection risk for
the general population because the vaccinia virus can be spread
only through close physical contact.
Nonetheless, Dr. Madelyn Kahana, the hospital's chief of pediatric
intensive care, said staff members treating the boy and his
mother were required to wear face masks and gloves, and that
the two had been placed in a special room with negative air
pressure, so all air would blow inward.
Kahana said the boy had been treated with a potent antiviral
drug, as well as with an anti-vaccinia agent supplied by the
CDC and the experimental drug ST-246, which was untried as a
therapy in humans.
She said the boy appeared to be improving this week, but will
probably lose 20 percent of his outer skin layer.